查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1262040

BPH 治療市場-全球行業規模、份額、趨勢、競爭、機會、預測，2018-2028 年藥物治療、手術治療、最終用戶、地區分析

Benign Prostate Hyperplasia Treatment Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Drug Treatment, By Surgical Treatment, By End User, By Region
出版日期: | 出版商: TechSci Research | 英文 113 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球良性前列腺增生 (BPH) 治療市場預計在 2024-2028 年預測期內將出現顯著增長，原因是男性老年人口的增加以及與良性前列腺增生相關的泌尿系統疾病的增加。 根據全球癌症觀察站的數據，2020 年全球大約報告了 19,292,789 例新癌症病例，其中前列腺癌最常見，報告了 14,14,259 例癌症病例。 此外，公眾缺乏對前列腺早期診斷和檢測的認識，預計將進一步推動 BPH 治療市場的增長。

產品發布提振市場

手術是比藥物治療更好的選擇，但由於手術割傷和燒傷會對身體造成術後傷害，患者往往會選擇藥物治療。 然而，微創手術的發展正在改變患者的態度，並為手術器械製造商帶來競爭優勢。 例如，Teleflex 於 2020 年 8 月推出了 Urolift，這是一種改進的用於治療 BPH 的組織控制系統。 可以在系統中放置一個小植入物，將前列腺小葉保持在縮回位置以打開尿道。 具有挑戰性前列腺解剖結構的患者，例如大的側葉和阻塞性中葉，是該設備的目標人群。 這些產品的推出有望推動市場增長。

研發成長

開髮用於治療前列腺癌等各種危及生命的疾病的新藥和手術的需求不斷增長，導致研發方法和活動的快速進步，從而導致市場增長。我們支持增長。 Clinicaltrials.gov 顯示，全球有 17 項處於不同發展階段的臨床試驗用於治療良性前列腺增生症 (BPH)。 這凸顯了世界範圍內為開發良性前列腺增生 (BPH) 藥物而進行的大量研究和開發，從而支持了市場的增長。 然而，2017 年 2 月，為了開展癌症聯合研究活動，成立了綜合腫瘤學中心 (CIO)。

醫療保健投資增加

由於先進的手術非常昂貴，因此癌症治療由政府資助。 Ayushman公司成立

Bharat Health and Wellness Centers (AB-HWC) 於 2018 年 2 月獲得印度政府批准，用於診斷和篩查三種常見癌症，即口腔癌、乳腺癌和宮頸癌。宣布。 2018 年發起的另一項舉措，即 Pradhan Mantri Jan Arogya Yojana，已根據其規範將癌症治療設施增加到一定的支出。 根據該計劃，化療和放療套餐以及外科腫瘤學作為內嵌醫院癌症護理的一部分被涵蓋，總共有 435 種癌症護理程序被定義為增加。

可自定義

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

  • 對其他市場參與者（最多 5 家公司）進行深入分析和概況分析

內容

第 1 章概述

  • 市場定義
  • 市場範圍
    • 目標市場
    • 研究目標年份
    • 主要市場細分

第二章研究方法論

  • 調查目的
  • 基線調查方法
  • 主要行業合作夥伴
  • 主要協會和次要信息
  • 調查方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章執行摘要

  • 市場概覽
  • 主要市場細分概述
  • 主要市場參與者概覽
  • 主要地區/國家概覽
  • 市場驅動因素、挑戰和趨勢

第 4 章 VOC（客戶之聲）

第 5 章 BPH 設備的全球市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 通過藥物治療（α-受體阻滯劑、5-α-還原□抑製劑、磷酸二酯□-5 抑製劑）
    • 通過手術方法（經尿道前列腺切除術 (TURP)、前列腺尿道提升術 (PUL)、前列腺切除術、激光手術、經尿道微波療法 (TUMT)、經尿道前列腺針切除術 (TUNA)），其他（Rezum 療法） , Urolift 療法, 其他)
    • 最終用戶（醫院/診所、門診手術中心、其他）
    • 按地區（北美、歐洲、亞太地區、南美、中東/非洲）
    • 按公司分類（2022 年）
  • 市場地圖
    • 通過藥物
    • 手術治療除外
    • 最終用戶
    • 按地區

第 6 章北美 BPH 設備市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 通過藥物
    • 手術治療除外
    • 最終用戶
    • 按國家
  • 北美：國家/地區分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲 BPH 藥物市場前景

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 通過藥物
    • 手術治療除外
    • 最終用戶
    • 按國家
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙

第8章亞太地區BPH藥物市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 通過藥物
    • 手術治療除外
    • 最終用戶
    • 按國家
  • 亞太地區：國家/地區分析
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞

第 9 章南美 BPH 治療市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 通過藥物
    • 手術治療除外
    • 最終用戶
    • 按國家
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲 BPH 藥物市場前景

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 通過藥物
    • 手術治療除外
    • 最終用戶
    • 按國家
  • MEA：國家分析
    • 阿聯酋 BPH 治療
    • 沙特阿拉伯的 BPH 治療
    • 南非 BPH 治療
    • Turkiye BPH 治療
    • 埃及 BPH 治療

第 11 章市場動態

  • 司機
    • 良性前列腺增生的患病率增加
    • 老年人口增加
    • 技術進步
  • 做
    • 昂貴的程序
    • 與技術相關的副作用
    • 缺乏進行侵入性手術的熟練專業人員

第12章市場趨勢與發展

  • 新藥開發
  • 新手術的開發

第13章臨床試驗分析

  • 正在進行的臨床試驗
  • 已完成臨床試驗
  • 已完成臨床試驗
  • 管道細分（按開發階段）
  • 管道細分（按狀態
  • 管道細分（按研究類型）
  • 按地區劃分的渠道細分
  • 臨床試驗熱圖

第14章競爭格局

  • 業務概覽
  • 提供的產品
  • 近期發展狀況
  • 財務狀況（針對上市公司）
  • 主要人員
    • Boston Scientific Corporation
    • Coloplast Corporation
    • Teleflex Incorporated
    • Olympus Corporation
    • Glaxo Smith Kline PLC
    • Eli Lily
    • Abott Laboratories
    • Medifocus Inc.
    • Urologix, LLC
    • Pfizer Inc

第 15 章戰略建議

第十六章關於研究公司/免責聲明

簡介目錄
Product Code: 14694

Global Benign Prostate Hyperplasia (BPH) Treatment Market is anticipated to observe impressive growth during the forecast period, 2024-2028, owing prevalence of benign prostatic hyperplasia rising global male geriatric population, rise in urological disorders associated with BPH. According to Global Cancer Observatory, in 2020, around 19,292,789 new cancer cases were reported worldwide, among which Prostate Cancer was the most prevalent type of cancer, accounting for 14,14,259 cases 2020. Additionally, the lack of awareness among the public for early prostate diagnosis and detection is further expected to drive the growth of the Benign Prostate Hyperplasia (BPH) Treatment Market.

The growing prevalence of fatal diseases has significantly increased the demand for different types of drugs and surgeries. Additionally, expansion in research & development activities being initiated by various governments, ambulatory surgical centers, and pharmaceutical companies across the globe is further expected to create opportunities for the growth of the Benign Prostate Hyperplasia (BPH) Treatment market in the coming years. According to Statista Research Department, as of now, the United States will be the leading country worldwide in terms of spending on research and development, with expenditure exceeding around USD679.4 billion.

According to the Cancer fact sheet, the cancer rates are highest in Australia/New Zealand and North America. Prostate cancer is the fourth most common cancer overall and the second most common cancer in men.

Product Launches Boost Market

Surgery is a superior alternative to treating BPH with medicine; however, due to the post-operative harm that surgical cuts and burns do to the body, patients tend to choose medication. Patients' perceptions have changed as a result of the development of minimally invasive techniques and surgical equipment makers now have a competitive advantage. For instance, Teleflex Inc. launched the UroLift improved tissue control system in August 2020 to treat BPH. To open the urethra, small implants that keep the prostate lobes in their retracted posture might be placed into the system. Patients with challenging prostatic anatomy, such as those who have large lateral lobes or an obstructive median lobe, are the target population for the device. These product launches are anticipated to boost the growth of the market.

Growth in Research & Development

Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need for developing novel drug/surgery for the treatment of different life-threatening diseases like prostate cancer. According to Clinicaltrials.gov, 17 clinical trials are in different phases of development across the globe for Benign Prostate Hyperplasia (BPH) Treatment. This clearly indicates that a lot of R&D is being done across the globe for developing Benign Prostate Hyperplasia (BPH) Treatment., thereby supporting the growth of the market. However, in February 2017, The Centre for Integrative Oncology (CIO) was established as a joint venture of the All India Institute of Ayurveda (AIIA) and the National Institute of Cancer Prevention and Research (NICPR-ICMR) with the intention of collaborative research activities in cancer.

Rising Investment in Healthcare

Advanced surgical therapies are very expensive; therefore, financial assistance is provided by the government for cancer treatment. An establishment of Ayushman

Bharat Health and Wellness Centers (AB-HWCs) were announced by the Government of India in February 2018 for the diagnosis and screening of three common cancers, i.e., oral, breast, and cervical. Another initiative launched in 2018, namely Pradhan Mantri Jan Arogya Yojana, surged treatment facilities for cancer up to a certain expenditure as per their norms. The chemotherapy and radiotherapy packages, along with surgical oncology, are covered as part of cancer treatment in the impaneled hospitals under the scheme, and a total of 435 procedures have been defined for the treatment of cancer.

Market Segmentation

The Global Benign Prostate Hyperplasia (BPH) Treatment Market can be segmented based on drug treatment, surgical treatment, end user, region, and competitional landscape. Based on drug treatment, the market can be categorized into alpha-blockers, 5-alpha reductase inhibitors, and Phosphodiesterase-5 Inhibitors. Based on surgical treatment, the market can be fragmented into transurethral resection of the prostate (TURP), prostatic urethral lift (PUL), Prostatectomy, laser surgery, transurethral microwave Technique (TUMT), transurethral needle ablation of the prostate (TUNA), and others. Based on end users, the market can be grouped into hospitals and clinics, ambulatory surgical centers, and others.

Company Profiles

Boston Scientific Corporation, Coloplast Corporation, Teleflex Incorporated, Olympus Corporation, Glaxo Smith Kline PLC, Eli Lily, Abbott Laboratories, Medifocus Inc., Urologix, LLC, and Pfizer Inc. are some of the key players operating in the Global Benign Prostate Hyperplasia (BPH) Treatment market.

Report Scope

In this report, Global Benign Prostate Hyperplasia (BPH) Treatment Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Benign Prostate Hyperplasia (BPH) Treatment Market, By Drug Treatment:

  • Alpha Blockers
  • 5-Alpha Reductase Inhibitors
  • Phosphodiesterase-5 inhibitors

Benign Prostate Hyperplasia (BPH) Treatment Market, By Surgical Treatment:

  • Transurethral resection of the prostate (TURP)
  • Prostatic Urethral Lift (PUL)
  • Prostatectomy
  • Laser surgery
  • Transurethral microwave Technique (TUMT)
  • Transurethral needle ablation of the prostate (TUNA)
  • Others

Benign Prostate Hyperplasia (BPH) Treatment Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

Benign Prostate Hyperplasia (BPH) Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Benign Prostate Hyperplasia (BPH) Treatment market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global BPH Devices Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Treatment (Alpha Blockers, 5-Alpha Reductase Inhibitors, and Phosphodiesterase-5 Inhibitors)
    • 5.2.2. By Surgical Treatment (Transurethral resection of the prostate (TURP), Prostatic Urethral Lift (PUL), Prostatectomy, laser surgery, Transurethral microwave Technique (TUMT), Transurethral needle ablation of the prostate (TUNA), and others (Rezum therapy, Urolift therapy, etc)
    • 5.2.3. By End User (hospitals and clinics, ambulatory surgical centres, and Others)
    • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.5. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Drug Treatment
    • 5.3.2. By Surgical Treatment
    • 5.3.3. By End User
    • 5.3.4. By Region

6. North America BPH Devices Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Treatment
    • 6.2.2. By Surgical Treatment
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States BPH Devices Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Treatment
        • 6.3.1.2.2. By Surgical Treatment
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada BPH Devices Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Treatment
        • 6.3.2.2.2. By Surgical Treatment
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico BPH Devices Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Treatment
        • 6.3.3.2.2. By Surgical Treatment
        • 6.3.3.2.3. By End User

7. Europe BPH Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Treatment
    • 7.2.2. By Surgical Treatment
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France BPH Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Treatment
        • 7.3.1.2.2. By Surgical Treatment
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany BPH Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Treatment
        • 7.3.2.2.2. By Surgical Treatment
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom BPH Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Treatment
        • 7.3.3.2.2. By Surgical Treatment
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy BPH Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Treatment
        • 7.3.4.2.2. By Surgical Treatment
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain BPH Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Treatment
        • 7.3.5.2.2. By Surgical Treatment
        • 7.3.5.2.3. By End User

8. Asia-Pacific BPH Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Treatment
    • 8.2.2. By Surgical Treatment
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China BPH Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Treatment
        • 8.3.1.2.2. By Surgical Treatment
        • 8.3.1.2.3. By End User
    • 8.3.2. Japan BPH Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Treatment
        • 8.3.2.2.2. By Surgical Treatment
        • 8.3.2.2.3. By End User
    • 8.3.3. India BPH Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Treatment
        • 8.3.3.2.2. By Surgical Treatment
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea BPH Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Treatment
        • 8.3.4.2.2. By Surgical Treatment
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia BPH Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Treatment
        • 8.3.5.2.2. By Surgical Treatment
        • 8.3.5.2.3. By End User

9. South America BPH Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Treatment
    • 9.2.2. By Surgical Treatment
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil BPH Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Treatment
        • 9.3.1.2.2. By Surgical Treatment
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina BPH Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Treatment
        • 9.3.2.2.2. By Surgical Treatment
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia BPH Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Treatment
        • 9.3.3.2.2. By Surgical Treatment
        • 9.3.3.2.3. By End User

10. Middle East and Africa BPH Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Treatment
    • 10.2.2. By Surgical Treatment
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE BPH Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Treatment
        • 10.3.1.2.2. By Surgical Treatment
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia BPH Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Treatment
        • 10.3.2.2.2. By Surgical Treatment
        • 10.3.2.2.3. By End User
    • 10.3.3. South Africa BPH Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Treatment
        • 10.3.3.2.2. By Surgical Treatment
        • 10.3.3.2.3. By End User
    • 10.3.4. Turkey BPH Treatment Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Drug Treatment
        • 10.3.4.2.2. By Surgical Treatment
        • 10.3.4.2.3. By End User
    • 10.3.5. Egypt BPH Treatment Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Drug Treatment
        • 10.3.5.2.2. By Surgical Treatment
        • 10.3.5.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
    • 11.1.1. Increasing prevalence of Benign Prostate Hyperplasia
    • 11.1.2. Growing geriatric population
    • 11.1.3. Technological Advancement
  • 11.2. Challenges
    • 11.2.1. High Cost of Procedure
    • 11.2.2. Side effects associated with the technique
    • 11.2.3. Lack of Skilled Professionals to conduct invasive surgeries

12. Market Trends & Developments

  • 12.1. Development of new drugs
  • 12.2. Development of new surgeries

13. Clinical Trial Analysis

  • 13.1. Ongoing Clinical Trials
  • 13.2. Completed Clinical Trials
  • 13.3. Terminated Clinical Trials
  • 13.4. Breakdown of Pipeline, By Development Phase
  • 13.5. Breakdown of Pipeline, By Status
  • 13.6. Breakdown of Pipeline, By Study Type
  • 13.7. Breakdown of Pipeline, By Region
  • 13.8. Clinical Trials Heat Map

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (In Case of Listed Companies)
  • 14.5. Key Personnel
    • 14.5.1. Boston Scientific Corporation
    • 14.5.2. Coloplast Corporation
    • 14.5.3. Teleflex Incorporated
    • 14.5.4. Olympus Corporation
    • 14.5.5. Glaxo Smith Kline PLC
    • 14.5.6. Eli Lily
    • 14.5.7. Abott Laboratories
    • 14.5.8. Medifocus Inc.
    • 14.5.9. Urologix, LLC
    • 14.5.10. Pfizer Inc

15. Strategic Recommendations

16. About Us and Disclaimer